Combination of an RXFP1 modulator and an SGLT2 inhibitor

JP2025519439A5Pending Publication Date: 2026-06-15ASTRAZENECA AB
0 Cites 0 Cited by

Patent Information

Application Number
JP2024571872
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-07
Filing Date
2023-06-06
Publication Date
2026-06-15

AI Technical Summary

Technical Problem

There is a continuing need for compounds that are modulators of RXFP1, which can offer improved modulation of RXFP1 compared to existing modulators, along with advantageous pharmacokinetic profiles and physical properties, for the treatment of medical conditions where RXFP1 modulation is beneficial, including hypertension.

Method used

The use of combinations of RXFP1 modulators with SGLT2 inhibitors, such as dapagliflozin, to treat conditions like hypertension, heart failure, and pulmonary hypertension, by administering therapeutically effective amounts of both types of compounds together.

Benefits of technology

The combination of RXFP1 modulators with SGLT2 inhibitors provides a synergistic effect in treating hypertension and related cardiovascular conditions, offering improved blood pressure control and potential benefits for heart failure and pulmonary hypertension patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This specification generally relates to a combination of an RXFP1 modulator and an SGLT2 inhibitor, and in particular to pharmaceutical compositions containing such combinations and methods of treatment using such combinations.
Need to check novelty before this filing date? Find Prior Art